Mainz Biomed BV (MYNZ) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $1.36 (+3.82%), Market cap $0.01B, 52-week low–high $0.59 ~ $2.13.
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Financial statements, price targets, institutional (13F) holdings and related news for Mainz Biomed BV are updated in real time on BlackAll Trade.
Mainz Biomed BV trades at $1.36 (+3.82%). Real-time quotes and charts are available on BlackAll Trade.
Mainz Biomed BV has a market cap of about $0.01B.
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular ge